Basal Cell Carcinomas Clinical Trial
— NPEFOfficial title:
Development of a Nanosecond Pulsed Electric Field System to Treat Skin Cancer
Human Basal Cell Carcinomas (BCCs) can be ablated by treating them with nanosecond pulsed electric fields (nsPEF)
Status | Completed |
Enrollment | 4 |
Est. completion date | June 2012 |
Est. primary completion date | June 2012 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: 1. Study subjects must have had diagnosed at least one BCCon their trunk 2. The subject is from 18-75 years of age, inclusive. 3. The subject must sign and date all informed consent statements. Exclusion Criteria: 1. The subject is exhibiting signs of a bacterial or viral infection, including fever. 2. The subject is unwilling to allow a biopsy of a malignant lesion for histological analysis. 3. The subject has a pace maker or other electronic device implanted |
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Children's Hospital Research Center Oakland | Oakland | California |
Lead Sponsor | Collaborator |
---|---|
Children's Hospital & Research Center Oakland |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Demonstrate the safety of PulseCure pulse generator and NanoBlate electrode and identify the optimal pulse number for treating basal cell carcinomas. | 1. Conduct a non-significant risk feasibility clinical trial treating BCCs on the trunk of up to 9 Basal Cell Nevus Syndrome patients with BioElectroMed's PulseCure pulse generator and Derm-Pulse electrode to both demonstrate the safety of nsPEF therapy and identify the optimal pulse number for ablating BCCs. | One year | Yes |
Secondary | Determine the efficacy of the PulseCure pulse generator using the optimal pulse number. | 2. Conduct a non-significant risk Pilot Clinical Trial treating BCCs on the trunk of 20 patients with sporadic BCCs using the optimal pulse number determined from the feasibility trial to assess the efficacy of this technique. | one year | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02828111 -
Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas
|
Phase 2 | |
Recruiting |
NCT01349361 -
Treatment of Basal Cell Carcinomas With Methyl Aminolevulinate and Daylight
|
Phase 2 | |
Recruiting |
NCT04389112 -
Study of Metabolic Changes in the Transformation Malignant Precancerous Skin Lesions
|
N/A | |
Terminated |
NCT02067104 -
Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention
|
Phase 2 |